1-3 of 3
Paul Clarke
Close
Sort by
Journal Articles

Multiomics Analysis of IMiD/CELMoD Resistant Multiple Myeloma Models Uncovers Novel and Targetable Vulnerabilities in the SREBP Lipid Synthesis Pathway

Sarah A. Bird, Amy Barber, Fernando J. Sialana, Marco P. Licciardello, Harvey Che, Habib Bouguenina, Yura Grabovska, Enze Liu, Yakinthi Chrisochoidou, Shannon Martin, Jyoti Choudhary, Brian A. Walker, Ian Collins, Paul Clarke, Charlotte Pawlyn
Journal: Blood
Blood (2022) 140 (Supplement 1): 600–601.
https://doi.org/10.1182/blood-2022-166444
Published: 2022
Journal Articles

The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma

Karen Menezes, PhD BSc, MSc, Grace Aram, MSc, Fabio Mirabella, PhD, David C Johnson, PhD, Amy L Sherborne, PhD, Richard S Houlston, MD PhD, Matthew D Cheeseman, PhD, Elisa Pasqua, PhD, Paul Clarke, PhD, Paul Workman, PhD, Keith Jones, PhD, Martin F Kaiser, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3072.
https://doi.org/10.1182/blood.V130.Suppl_1.3072.3072
Published: 2017
Journal Articles

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Charlotte Pawlyn, MB BChir, Michael Bright, PhD, Amy Buros, PhD, Caleb K. Stein, MS, Zoe Walters, PhD, Lauren Aronson, PhD, Fabio Mirabella, PhD, Martin F Kaiser, MD, John R Jones, MD, Brian A Walker, PhD, Graham H Jackson, MD PhD, Paul Clarke, PhD, Leif Bergsagel, MD, Paul Workman, PhD, Marta Chesi, PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD
Journal: Blood
Blood (2016) 128 (22): 3289.
https://doi.org/10.1182/blood.V128.22.3289.3289
Published: 2016